The recently reported Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) showed the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduced the risk of hospital admission for worsening heart failure, increased survival and improved symptoms in patients with heart failure with reduced ejection fraction (HFrEF).^1–3 Although SGLT2 inhibitors had been developed as glucose-lowering treatments for patients with type 2 diabetes, approximately half the patients in DAPA-HF did not have type 2 diabetes.^1–3 The benefits of dapagliflozin in DAPA-HF were of a similar magnitude in participants without diabetes to the benefits obtained in individuals with diabetes. Importantly, in both groups of patients, dapagliflozin in patients with HFrEF were observed when dapagliflozin was added to excellent background disease-modifying therapy for heart failure.

中文翻译：

---

Dapagliflozin 和预防心力衰竭试验 (DAPA-HF) 中的不良后果

最近报道的达格列净和预防心力衰竭不良结果试验 (DAPA-HF) 表明，钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂达格列净降低了心力衰竭恶化的住院风险，提高了心脏病患者的生存率并改善了症状。射血分数降低（HFrEF）。^1-3虽然 SGLT2 抑制剂已被开发用于 2 型糖尿病患者的降糖治疗，但 DAPA-HF 中大约一半的患者没有 2 型糖尿病。^1-3dapagliflozin 在 DAPA-HF 中的益处在没有糖尿病的参与者中与在糖尿病患者中获得的益处具有相似的程度。重要的是，在两组患者中，当将 dapagliflozin 添加到优秀的心力衰竭背景疾病改善治疗中时，在 HFrEF 患者中观察到 dapagliflozin。